JPMorgan analyst Chris Schott reinstated coverage of Eli Lilly with an Overweight rating and $140 price target. He also added the shares to his firm's Analyst Focus List. The analyst continues to see Lilly as the best positioned of his large-cap names based on a combination of "healthy" core product growth, a "growing" portfolio of new launches and next-generation pipeline assets, a "significant margin expansion story," and "several sources of upside to near- and long-term numbers." Schott expects Eli Lilly to generate 6%-8% sales growth and mid-teens annual earnings growth through much of the decade. The stock represents a top pick in his coverage universe.